Aoxing Pharmaceutical Company, Inc. (AOXG)
Stock Price:
$0.0100 USD
-0.0017 (-14.53%)
Updated Aug 10, 2020 4:00 PM EDT - End of day
Key Info
| Market Cap |
762,090 |
| Revenue (ttm) |
30.11M |
| Net Income (ttm) |
-1.46M |
| Shares Out |
76.21M |
| EPS (ttm) |
-0.02 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 10, 2020 |
| Last Price |
$0.0100 |
| Previous Close |
$0.0117 |
| Change ($) |
-0.0017 |
| Change (%) |
-14.53% |
| Day's Open |
0.0090 |
| Day's Range |
0.0090 - 0.0090 |
| Day's Volume |
225 |
| 52-Week Range |
0.0056 - 0.0290 |
More Stats
| Market Cap |
762,090 |
| Enterprise Value |
20.62M |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
76.21M |
| Float |
46.19M |
| EPS (basic) |
-0.02 |
| EPS (diluted) |
-0.02 |
| FCF / Share |
-0.02 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
13,236 |
| Short Ratio |
0.03 |
| Short % of Float |
0.03% |
| Beta |
3.47 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
0.03 |
| PB Ratio |
0.07 |
| Revenue |
30.11M |
| Operating Income |
967,218 |
| Net Income |
-1.46M |
| Free Cash Flow |
-1.39M |
| Net Cash |
-19.86M |
| Net Cash / Share |
-0.26 |
| Gross Margin |
81.56% |
| Operating Margin |
3.21% |
| Profit Margin |
-4.90% |
| FCF Margin |
-4.63% |
| ROA |
1.00% |
| ROE |
-7.56% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Low
4.00
Current: $0.0100
High
4.00
Target: 4.00
*Average 12-month price target from 1 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|
| Revenue | 32.33 | 25.48 | 12.74 | 10.83 | 8.13 | 6.65 | 6.12 | 8.94 | 7.07 | 1.94 |
| Revenue Growth | 26.88% | 100.02% | 17.63% | 33.14% | 22.3% | 8.75% | -31.61% | 26.57% | 264.43% | - |
| Gross Profit | 24.55 | 19.79 | 5.81 | 6.27 | 4.90 | 3.32 | 3.77 | 3.81 | 3.23 | 0.90 |
| Operating Income | 6.23 | 8.70 | -3.33 | -14.22 | -14.55 | -4.86 | -3.58 | -6.35 | -3.58 | -1.41 |
| Net Income | 2.06 | 5.49 | -8.22 | -16.80 | -15.82 | -7.41 | -0.83 | -2.45 | 3.65 | -14.77 |
| Shares Outstanding | 73.70 | 63.11 | 49.86 | 49.75 | 49.35 | 46.58 | 45.58 | 41.20 | 24.62 | 20.05 |
| Earnings Per Share | 0.03 | 0.09 | -0.16 | -0.34 | -0.32 | -0.16 | -0.02 | -0.06 | 0.16 | -0.70 |
| EPS Growth | -66.67% | - | - | - | - | - | - | - | - | - |
| Operating Cash Flow | -0.53 | 3.03 | -7.73 | -8.32 | -1.33 | -2.67 | -3.98 | -0.64 | -0.98 | -14.21 |
| Capital Expenditures | -0.12 | -2.71 | -0.27 | -0.44 | -0.75 | -1.37 | -2.00 | -2.23 | -1.48 | -1.11 |
| Free Cash Flow | -0.65 | 0.32 | -8.00 | -8.76 | -2.08 | -4.05 | -5.97 | -2.87 | -2.46 | -15.32 |
| Cash & Equivalents | 7.68 | 5.37 | 2.33 | 4.01 | 3.68 | 2.77 | 3.99 | 1.27 | 1.57 | 1.51 |
| Total Debt | 25.47 | 30.45 | 32.04 | 25.56 | 15.66 | 12.47 | 14.84 | 17.91 | 15.28 | 14.17 |
| Net Cash / Debt | -17.79 | -25.07 | -29.71 | -21.55 | -11.98 | -9.70 | -10.86 | -16.64 | -13.71 | -12.66 |
| Assets | 56.23 | 53.04 | 38.07 | 39.73 | 45.09 | 55.87 | 58.33 | 56.74 | 56.13 | 21.18 |
| Liabilities | 38.16 | 42.98 | 43.74 | 35.15 | 23.82 | 20.16 | 24.02 | 32.11 | 30.99 | 30.72 |
| Book Value | 19.14 | 11.24 | -2.51 | 5.67 | 21.88 | 36.31 | 34.57 | 24.89 | 25.14 | -10.72 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Aoxing Pharmaceutical Company, Inc. |
| Country |
United States |
| Employees |
346 |
| CEO |
Zhen Jiang Yue |
Stock Information
| Ticker Symbol |
AOXG |
| Stock Exchange |
US OTC |
| Unique Identifier |
OTCMKTS: AOXG |
Description
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. is headquartered in Shijiazhuang, China.